AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

AlphaQuest LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 93.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,080 shares of the biotechnology company’s stock after selling 30,501 shares during the quarter. AlphaQuest LLC’s holdings in Arrowhead Pharmaceuticals were worth $72,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Marshall Wace LLP lifted its stake in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares during the last quarter. Norges Bank acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $30,414,000. Invesco Ltd. lifted its stake in Arrowhead Pharmaceuticals by 142.8% in the 2nd quarter. Invesco Ltd. now owns 762,665 shares of the biotechnology company’s stock valued at $12,050,000 after purchasing an additional 448,585 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after purchasing an additional 447,456 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in Arrowhead Pharmaceuticals by 1,388.6% during the third quarter. Assenagon Asset Management S.A. now owns 380,625 shares of the biotechnology company’s stock worth $13,128,000 after buying an additional 355,056 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Early reports show a “strong start” to REDEMPLO commercialization, which supports near-term revenue traction and helps explain buying interest despite mixed guidance from some analysts. ARWR: Strong Start for REDEMPLO Commercialization
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target while raising several multi‑year estimates (notably FY2028–FY2030 upside and some quarterly lifts), signaling confidence in Arrowhead’s longer-term pipeline and commercialization prospects — a bullish catalyst for investors focused on growth potential. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Neutral Sentiment: Short‑interest data reported zero shares and NaN changes for mid‑February (likely a reporting/data anomaly). Current short‑interest ratio is shown as 0.0 days — this item appears to have no actionable impact on supply/demand given the inconsistent figures.
• Negative Sentiment: Zacks Research cut multiple near‑term and longer‑term EPS forecasts (Q2–Q4 2026 and FY2026–FY2028), lowering Q2–Q4 2026 quarter estimates and materially reducing FY2026 and FY2027 forecasts. Those downward revisions add pressure to near‑term earnings expectations and may weigh on sentiment for value/earnings‑driven traders.

Analyst Ratings Changes

Several research analysts have recently commented on ARWR shares. Royal Bank Of Canada lifted their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. The Goldman Sachs Group raised their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, B. Riley Financial lifted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $63.82 on Friday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The firm’s 50-day simple moving average is $67.03 and its 200 day simple moving average is $45.26. The firm has a market cap of $8.94 billion, a price-to-earnings ratio of 41.71 and a beta of 1.21.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. During the same quarter in the previous year, the company earned ($1.39) EPS. The business’s revenue for the quarter was up 10461.3% on a year-over-year basis. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 40,164 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the sale, the insider directly owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. This represents a 18.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the transaction, the chief operating officer owned 474,908 shares in the company, valued at $29,971,443.88. The trade was a 9.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 510,836 shares of company stock valued at $33,603,060 over the last ninety days. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.